131 related articles for article (PubMed ID: 19530242)
1. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.
Marra M; Santini D; Meo G; Vincenzi B; Zappavigna S; Baldi A; Rosolowski M; Tonini G; Loeffler M; Lupu R; Addeo SR; Abbruzzese A; Budillon A; Caraglia M
Int J Cancer; 2009 Nov; 125(9):2004-13. PubMed ID: 19530242
[TBL] [Abstract][Full Text] [Related]
2. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
3. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
Li YY; Chang JW; Liu YC; Wang CH; Chang HJ; Tsai MC; Su SP; Yeh KY
Anticancer Drugs; 2011 Jan; 22(1):89-98. PubMed ID: 20926944
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells.
Nogawa M; Yuasa T; Kimura S; Kuroda J; Segawa H; Sato K; Yokota A; Koizumi M; Maekawa T
Oncol Res; 2005; 15(1):1-9. PubMed ID: 15839301
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
[TBL] [Abstract][Full Text] [Related]
8. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Sonnemann J; Bumbul B; Beck JF
Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.
Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.
Valenti MT; Giannini S; Donatelli L; Realdi G; Lo Cascio V; Dalle Carbonare L
J Endocrinol Invest; 2010 Apr; 33(4):244-9. PubMed ID: 19915386
[TBL] [Abstract][Full Text] [Related]
13. Anticancer effects of zoledronic acid against human osteosarcoma cells.
Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
16. Suppression of human prostate cancer PC-3 cell growth by N-acetylcysteine involves over-expression of Cyr61.
Lee YJ; Lee DM; Lee CH; Heo SH; Won SY; Im JH; Cho MK; Nam HS; Lee SH
Toxicol In Vitro; 2011 Feb; 25(1):199-205. PubMed ID: 21055460
[TBL] [Abstract][Full Text] [Related]
17. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
Moriceau G; Ory B; Mitrofan L; Riganti C; Blanchard F; Brion R; Charrier C; Battaglia S; Pilet P; Denis MG; Shultz LD; Mönkkönen J; Rédini F; Heymann D
Cancer Res; 2010 Dec; 70(24):10329-39. PubMed ID: 20971812
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid: an unending tale for an antiresorptive agent.
Caraglia M; Marra M; Naviglio S; Botti G; Addeo R; Abbruzzese A
Expert Opin Pharmacother; 2010 Jan; 11(1):141-54. PubMed ID: 20001436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]